(Total Views: 352)
Posted On: 01/08/2020 3:38:00 PM
Post# of 182
NetworkNewsBreaks – Grapefruit Boulevard Investments Inc. (IGNG) Reports Positive Time-Release Efficacy Results from Initial THC Patchless Patch Laboratory Testing
Grapefruit Boulevard Investments, a Los Angeles based California corporation and wholly owned subsidiary of Imaging3, Inc. (OTCQB: IGNG), (collectively “Grapefruit”), this morning reported successful results from the initial round of laboratory testing of the time release efficacy of its patented THC Patchless Patch(TM) topical cream. The results showed that the product can deliver a consistent, reliable pre-defined dose of THC via a user’s skin throughout an estimated ten-hour time period. “The results of these tests of Grapefruit’s patented THC Cannabinoid time-release Patchless Patch have demonstrated its efficacy. Grapefruit believes that the consistent and sustained delivery of THC Cannabinoids over a defined period has the potential to change the manner in which chronic long-term pain and other disorders are managed. It also has the potential to provide an alternative to the use of highly addictive opioids for the treatment of chronic pain. Our hope is that this potentially game-changing technology will allow people who suffer from chronic pain and other disorders to lead more active and productive lives. Furthermore, our THC Patchless Patch has obvious applications in the recreational cannabis context for use at events such as concerts and movies as well as transcontinental flights. We are targeting the end of the Second Quarter of 2020 to bring the product to market. We will keep our shareholders and the public apprised of further developments with the THC Patchless Patch as they occur,” Grapefruit CEO Bradley J. Yourist stated in the news release.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Grapefruit Boulevard Investments, a Los Angeles based California corporation and wholly owned subsidiary of Imaging3, Inc. (OTCQB: IGNG), (collectively “Grapefruit”), this morning reported successful results from the initial round of laboratory testing of the time release efficacy of its patented THC Patchless Patch(TM) topical cream. The results showed that the product can deliver a consistent, reliable pre-defined dose of THC via a user’s skin throughout an estimated ten-hour time period. “The results of these tests of Grapefruit’s patented THC Cannabinoid time-release Patchless Patch have demonstrated its efficacy. Grapefruit believes that the consistent and sustained delivery of THC Cannabinoids over a defined period has the potential to change the manner in which chronic long-term pain and other disorders are managed. It also has the potential to provide an alternative to the use of highly addictive opioids for the treatment of chronic pain. Our hope is that this potentially game-changing technology will allow people who suffer from chronic pain and other disorders to lead more active and productive lives. Furthermore, our THC Patchless Patch has obvious applications in the recreational cannabis context for use at events such as concerts and movies as well as transcontinental flights. We are targeting the end of the Second Quarter of 2020 to bring the product to market. We will keep our shareholders and the public apprised of further developments with the THC Patchless Patch as they occur,” Grapefruit CEO Bradley J. Yourist stated in the news release.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
